Apellis Pharmaceuticals, Inc. — Director's Dealing 2022

Feb 1, 2022

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Apellis Pharmaceuticals, Inc. (APLS)
CIK: 0001492422
Period of Report: 2022-01-28

Reporting Person: SCHEIBLER LUKAS (CHIEF INNOVATION OFFICER)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2022-01-28	Common Stock	F	642	$38.59	Disposed	55090	Direct
2022-01-31	Common Stock	S	1233	$38.47	Disposed	53857	Direct

Footnotes

F1: This represents shares used to cover tax withholding on a Restricted Stock Unit release.

F2: This is a scheduled sale from 10B5-1 trading plan.